Public, exchange-traded

SLRC — SLR Investment Corp

SLR Investment Corp is a business development company managed by SLR Capital Partners. Strategy: cash flow lending, asset-based, life sciences.

What SpreadVista tracks for SLRC

•Marks-to-par across the portfolio. Fair value as a fraction of par cost — the canonical health signal for a private-credit position — read from SLRC's own iXBRL tags and tracked quarter-over-quarter. A mark needs a par basis to exist, and SLRC reports one on 87% of the positions we serve; the rest (equity stakes, warrants, untagged principal) are shown without one rather than estimated.
•Reported NAV per share. SLRC's net asset value per share as filed, and — for exchange-listed tickers — the premium or discount its market price carries to that NAV.
•Non-accrual positions. The SLRC positions we tied to a non-accrual disclosure in the filer's own footnotes, and the dollar exposure behind them. A position is flagged only where the filing says so — every other position is carried as unknown, never as performing — so read this as a floor on SLRC's non-accruals, not a complete list.
•Top issuers by fair value. SLRC's concentration profile — the largest 10/25/50 exposures with mark and maturity context.
•Spread surface vs comparable BDCs. Where SLRC's positions sit on the credit-spread surface relative to peer-group BDCs holding similar credits, across the 60.5% of its positions that carry a tagged spread over a reference rate.
•Cross-vehicle issuer exposure. Which other BDCs and interval funds hold the same credits as SLRC — a contagion-risk view incumbents charge $20K–200K per seat for.

See SLRC's full analytics

Free to research. Every SLRC position we serve, every cross-vehicle overlap — sourced directly from primary regulatory disclosures, with the methodology and the coverage gaps shown on every chart.

Get Free Access

About SLRC

Ticker: SLRC
Legal name: SLR Investment Corp
Manager / Advisor: SLR Capital Partners
Category: Public, exchange-traded
Strategy: Cash flow lending, asset-based, life sciences
Fiscal year end: 12-31

Related concepts

Plain-English explanations of the concepts behind BDC analysis:

What SpreadVista tracks for SLRC

•Marks-to-par across the portfolio. Fair value as a fraction of par cost — the canonical health signal for a private-credit position — read from SLRC's own iXBRL tags and tracked quarter-over-quarter. A mark needs a par basis to exist, and SLRC reports one on 87% of the positions we serve; the rest (equity stakes, warrants, untagged principal) are shown without one rather than estimated.

•Reported NAV per share. SLRC's net asset value per share as filed, and — for exchange-listed tickers — the premium or discount its market price carries to that NAV.

•Non-accrual positions. The SLRC positions we tied to a non-accrual disclosure in the filer's own footnotes, and the dollar exposure behind them. A position is flagged only where the filing says so — every other position is carried as unknown, never as performing — so read this as a floor on SLRC's non-accruals, not a complete list.

•Top issuers by fair value. SLRC's concentration profile — the largest 10/25/50 exposures with mark and maturity context.

•Spread surface vs comparable BDCs. Where SLRC's positions sit on the credit-spread surface relative to peer-group BDCs holding similar credits, across the 60.5% of its positions that carry a tagged spread over a reference rate.

•Cross-vehicle issuer exposure. Which other BDCs and interval funds hold the same credits as SLRC — a contagion-risk view incumbents charge $20K–200K per seat for.